The RAPS store will be under maintenance Saturday, 7 December between 6 AM and 12 PM.  Store functionality may be unavailable at times during this window.
We apologize for any inconvenience caused during this time.

Regulatory Focus™ > News Articles > Corruption Risk: Responding to Critical Issues in the Pharmaceutical Industry

Corruption Risk: Responding to Critical Issues in the Pharmaceutical Industry

Posted 01 November 2010 | By

As regulators and law enforcement officials in the US and abroad shine brighter spotlights on the pharmaceutical industry, it is more important than ever for life sciences companies to have programs to evaluate, mitigate and monitor corruption risk. A robust anti-corruption compliance program provides a critical "rule book" for life sciences companies conducting business in today's global economy.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe